Drug Watch

New research reveals ART12.11, a cannabidiol:tetramethylpyrazine cocrystal, significantly enhances mood regulation, outperforming traditional cannabidiol in treating mood and anxiety disorders.

Alto Neuroscience reveals EEG biomarkers effectively distinguish patients with schizophrenia, enhancing treatment precision and advancing psychiatric research.

Tonmya, the first new FDA-approved fibromyalgia treatment in 15 years, shows promise in reducing pain and improving patient outcomes according to newly released data.

FDA approves Amneal Pharmaceuticals' new long-acting injectable risperidone for schizophrenia, enhancing treatment options and potentially patient adherence.

Alixorexton shows promise as a treatment for narcolepsy type 1, and is the first orexin 2 receptor agonist to demonstrate clinically meaningful and statistically significant impact on wakefulness, cognition, and fatigue with once-daily dosing across a range of doses.

Cognition Therapeutics advances zervimesine phase 2 trial, exploring its potential to slow cognitive decline in Alzheimer disease patients.

Neuphoria Therapeutics announces successful enrollment in a pivotal trial for BNC-210, a promising treatment for social anxiety disorder.

Achieve Life Sciences gains FDA acceptance for cytisinicline, a promising new drug for smoking cessation, showing significant abstinence rates in trials.

The FDA has approved the Leqembi subcutaneous autoinjector for at-home Alzheimer disease treatment.

Check out the pipeline updates from August!

NRX-100, a preservative-free ketamine, is granted expanded access for treatment of suicidal ideation in depression, offering new hope for patients.

BioXcel Therapeutics reveals promising phase 3 results from the SERENITY trial, paving the way for potential at-home treatment of agitation in bipolar disorder and schizophrenia.

Incannex Healthcare shared positive data from its phase 2 clinical trial of PSX-001, a psilocybin-assisted psychotherapy treatment for generalized anxiety disorder.

Leqembi for the treatment of Alzheimer disease has been launched in Austria on August 25, 2025, and will be launched in Germany on September 1, 2025—the first launches in the EU.

Altimmune's pemvidutide gains FDA Fast Track designation for alcohol use disorder.

BioXcel Therapeutics advances BXCL501 for outpatient treatment of agitation in bipolar disorder and schizophrenia, receiving positive FDA feedback in its pre-sNDA meeting discussion.

FDA approves Tonmya, a groundbreaking fibromyalgia treatment, offering hope for pain relief after 15 years without new options.

PharmaTher's KETARx gains FDA approval, paving the way for innovative ketamine treatments in pain management and mental health disorders.

NRx Pharmaceuticals secures FDA Fast Track designation for NRX-100, a preservation-free formulation of intravenous ketamine for suicidal ideation in depression.

Stay updated on key psychopharmacology developments, including new treatments for schizophrenia and breakthroughs in depression therapy.

The FDA has granted a Type C Meeting to Nutriband for their Aversa fentanyl patch, which aims to revolutionize pain management with its innovative abuse-deterrent technology.

Boehringer Ingelheim and Click Therapeutics achieve breakthrough results in treating negative schizophrenia symptoms with investigational prescription digital therapeutic CT-155.

Adial Pharmaceuticals just wrapped a successful end of phase 2 meeting with the FDA and will now advance its innovative treatment for alcohol use disorder, AD04.

Biogen's zuranolone gains positive opinion for treating postpartum depression, promising rapid symptom relief and potential EU approval by 2025.

Check out the pipeline updates from July!